Drug intelligence / Profile preview

Endura-KT

Development stage: Unknown
Lead developer: Ventis Pharma
Modality: Small Molecules
Administration: Topical, Buccal

Overview

Endura-KT is a compounded local anesthetic combination developed by Ventis Pharma specifically for pain management during dental and oral procedures. It is formulated as an FDA 503B compounded medication containing lidocaine, tetracaine, and epinephrine. Lidocaine and tetracaine are local anesthetics that work by blocking voltage-gated sodium channels, thereby inhibiting nerve impulse conduction and providing analgesia. Epinephrine is included as a vasoconstrictor to reduce local blood flow, which helps to prolong the duration of the anesthetic effect and minimize systemic absorption of the active ingredients.

Brand names: Endura-KT
Other names: lidocaine + tetracaine + epinephrine

Targets

ADRB1 (β1)ADRA1A (α1A)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on Endura-KT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endura-KT.

Explore the full profile